Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Opko Health, Inc.

NASDAQ: OPK · Life Sciences · 5 alerts · CIK 944809

Share price
$1.62Close, Nov 16
Market cap
$1.2B
Shares outstanding
742.51MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Opko Health, Inc. filings on SEC EDGAR ↗

4:07 PM ET Form 4
Insider Selling

Opko Health Director John A. Paganelli Sells $16.7K of Stock

John A. Paganelli, Director, sold 9,175 shares of Opko Health, Inc. at $1.82 a share, worth $16.7K in total on Nov 5, 2026. Shares held after the trade: 0 (-100.0%).

Value
$16.7K
Shares
9,175
Price
$1.82
Role
Director
Holding change
-100.0%
Trade date
Nov 5, 2026
4:24 PM ET 8-K
Financial Results

Opko Health Financial Results

OPKO Health reported its third quarter 2026 financial results, highlighting a pending $722 million sale of its BioReference diagnostic operations to Labcorp. The company also expanded its financing with HealthCare Royalty by $125 million and advanced several clinical programs, including dosing the first participant in a Phase 1/2a trial for acromegaly.

Term
Q3 2026
4:08 PM ET 8-K
Divestiture

Opko Health Divestiture to Laboratory Corporation of America Holdings for $722M

OPKO Health and its subsidiary BioReference Health entered into a definitive agreement to sell certain assets of their clinical and anatomic pathology laboratory testing business to Labcorp for $722 million in cash. The deal includes clinical and women’s health testing, urology, and the proprietary 4Kscore prostate cancer test, with OPKO eligible for up to an additional $150 million in milestone payments over ten years based on 4Kscore revenue. The transaction is subject to HSR Clearance and customary closing conditions, with a target completion date by April 14, 2027.

Value
$722M
Counterparty
Laboratory Corporation of America Holdings
Term
up to 10 years
4:13 PM ET 8-K
Loan & Debt

Opko Health $121M Debt Financing with U.S. Bank Trust Company, National Association

OPKO Health announced that its 3.75% Convertible Senior Notes due 2029 have become convertible by holders through December 31, 2026, after the stock price exceeded 130% of the conversion price for a specified period. The company has elected to settle these conversion obligations in shares of common stock rather than cash. Approximately $121 million in principal amount of these notes remains outstanding.

Value
$121M
Counterparty
U.S. Bank Trust Company, National Association

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.